Biotech Values

[DewDiligence]

Understood. PFE's “Prevnar 20” follow-on vaccine has antigens for 20 pneumococcus strains rather than the 13 in Prevnar 13. It is based on the same technology as Prevnar 13.

MRK's follow-on product, V114, has antigens for 15 strains and uses an updated technology. Pneumovax, MRK’s first-generation pneumococcus vaccine, has 23 strains but its 1980s technology generally produces a weaker immunogenic response than Prevnar 13 and the second-generation candidates.